CClinicalTrials.gg
RecruitingNCT05742178NYC CONNECTUpdated Dec 18, 2025

NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation

An interventional study of Patient Navigation (PN) - More Intensive and Educational Materials in Cancer Screening, sponsored by NYU Langone Health. Recruiting at 2 sites in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Screening

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
2,160
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Study summary

NYC CONNECT will carry out a randomized controlled trial (RCT) which will assess the relative effectiveness of two evidence-based strategies to increase cancer screening rates for breast, cervical, and colorectal cancer. The RCT will compare the effectiveness of using a combination of 1) culturally and linguistically tailored cancer education materials and 2) community health workers (CHWs) to provide navigation services for cancer screening (the "patient navigation" [PN] arm) versus providing culturally and linguistically tailored cancer education only (the "less intensive" [LI] arm). The study population will include individuals who are due for breast, cervical, or colorectal cancer screening. All individuals recruited to the study will be provided navigation for unmet social determinants of health (SDH) needs.

02

Conditions studied

  • Cancer Screening
03

In context

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Women between the ages of 21 and 75 years;
  • Men between the ages of 45 and 75 years;
  • Women (40-74 years) who have not had a mammogram in the past 12 months, a Pap smear in the last 3 years (21-64 years old) or HPV test in the last 5 years (30-64 years old), or women 45-75 years old who are not up-to-date on colorectal cancer screening (Fecal occult blood test (FOBT)/Fecal immunochemical test (FIT) past year, computerized tomography (CT) colonography or sigmoidoscopy past 5 years, or colonoscopy past 10 years);
  • Men not up-to-date on colorectal cancer screening (FOBT/FIT past year, computerized tomography (CT) colonography or sigmoidoscopy past 5 years, or colonoscopy past 10 years);
  • Must speak either English, Spanish, Haitian-Creole, French, or Chinese (Mandarin and Cantonese);
  • Lives in East Flatbush (zip codes: 11236, 11203, 11212, 11226); Sunset Park (zip codes: 11215, 11220, 11232); Highbridge (zip code 10452, 10455, 10451); or Morrisania (zip codes: 10456, 10459)

Exclusion criteria

Exclusion Criteria:

  • Previous or current diagnosis of any cancer;
  • Pregnancy (breast and cervical cancer only);
  • Current participation in an existing cancer navigation program;
  • Currently in hospice care;
  • At least 66 years of age with advanced illness or frailty or who live in long-term institution for more than 90 days;
  • Bilateral mastectomy or right and left unilateral mastectomy (breast cancer only);
  • Hysterectomy with no residual cervix (cervical cancer only);
  • Total colectomy (colorectal cancer only).
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,160 participants (estimated)

Study arms

  • Experimental
    Patient Navigation (PN)

    Participants randomized to the PN arm will receive community health worker (CHW)-administered PN for cancer screening + social service needs + culturally and linguistically tailored cancer education. All individuals will complete a survey at baseline, 3 months, and 6 months.

    Behavioral: Patient Navigation (PN) - More Intensive · Behavioral: Educational Materials

  • Active comparator
    Less Intensive (LI)

    Participants randomized to LI arm will receive PN to social service needs + culturally and linguistically tailored cancer education materials. All individuals will complete a survey at baseline, 3 months, and 6 months. Once a participant randomized to the LI arm completes the 6-month survey, they will have the option to receive all navigational support provided by CHWs to individuals randomized to the PN arm.

    Behavioral: Educational Materials · Behavioral: Patient Navigation (PN) - Less Intensive

Interventions

  • BehavioralPatient Navigation (PN) - More Intensive

    The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for cancer screening status and social needs and provide navigational support to cancer screening and social services.

  • BehavioralEducational Materials

    Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.

  • BehavioralPatient Navigation (PN) - Less Intensive

    The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for social needs and provide navigational support to social services.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Receive at Least 1 Cancer Screening at 6 Months After Study Enrollment

    Cancer screening defined as a breast, cervical, or colorectal cancer screening.

    Time frame: Up to Month 6

07

Study locations

2 of 2 sites recruiting
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
  • Albert Einstein College of Medicine
    The Bronx, New York 10461, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Madison.LeCroy@nyulangone.org. Data will also be available for 5 years at a data repository, appropriately selected with the guidance of Nicole Contaxis, NYULH Data Catalog Coordinator. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05742178
Lead sponsor
NYU Langone Health
Collaborators
Centers for Disease Control and Prevention
Responsible party
Sponsor
First posted
Feb 23, 2023
Start date
Jul 5, 2023
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Dec 18, 2025

Study contacts

Chau Trinh-Shevrin, DrPH
Contact
chau.trinh@nyulangone.org
646-501-3480
Perla Chebli, PhD
Contact
perla.chebli@nyulangone.org
646-501-3524
Chau Trinh, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion